Aafact® consists of a protein fraction prepared from fresh-frozen, human plasma. The product is supplied as a sterile and pyrogen-free powder. A vial contains respectively 0.1 or 0.2 g of freeze-dried powder corresponding with respectively 500 and 1000 International Units (IU) of factor VIII.



Aafact® is intended for use in cases of acute haemorrhage, pre-operative and postoperative treatment and prophylaxis in haemophilia A patients (congenital factor VIII deficiency) and in patients with an acquired reduction in factor VIII activity.

Kontra Indikasi :

No contra-indications for the use of Aafact® are known.

Efek Samping :

Some patients may experience reactions of an allergic nature. Mild reaction such as urticaria may be treated with antihistamines and corticosteroids. In the case of more severe reactions (e.g. anaphylactic shock) administration of the product should be stopped immediately, after which the reaction should first be treated with a high dose of corticosteroids and then with adrenaline, slowly administered intravenously (not by the intramuscular route!).

Peringatan :


Aturan Pakai :

The dosage in treatment and prophylaxis of haemorrhages depends on the severity of the disease, as well as the clinical condition and the weight of the patient. At the same time account should be taken of the half life of the factor VIII being administered.

Cara Penyimpanan :

Aafact® should be stored 2 - 8 °C, protected from light.

Kemasan :

Aafact® (500 IU) : - vial : 8 ml-vial, glass type I - vial WFI : 5 ml-vial, glass type I of solvent - stopper : bromobutyl rubber - cap : aluminium flip-off seal

No Reg : DKI1306700680A1